CompletedPhase 2

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

United States33 participantsStarted 2017-07-22

Plain-language summary

The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Positive nitrites
✕. White blood cell count greater than 15/hpf (high powered field)
✕. Positive urine culture \[defined as a single isolated bacterial species population of greater than 100,000 Colony Forming Units (CFU)\]

What they're measuring

Spontaneous Stone Passage Using Fisher's Exact Test

Timeframe: 30 days

Trial details

NCT IDNCT02744430

SponsorBaylor College of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10-31

Results submitted2020-10-02

View on ClinicalTrials.gov More Ureteral Obstruction trials